A. cinnamomea

USFDA recognized Antrodia cinnamomea mycelia (NDIN No.1170)

Retrieved on: 
Wednesday, May 19, 2021

The USFDA NDI acknowledgement without objection to Greenyn\'s Antromax was the 1st notification after numerous attempts in the past 14 years.

Key Points: 
  • The USFDA NDI acknowledgement without objection to Greenyn\'s Antromax was the 1st notification after numerous attempts in the past 14 years.
  • We are honored to establish a stepping-stone for the A. cinnamomea to the US health markets estimated at 10 billion US dollars.\nDr.
  • It was a great feat for Greenyn, and will certainly boost the morale of the Antrodia industry to devote more resources in the US market.\nA.
  • It is foreseeable that the health benefits of A. cinnamomea to the world during covid-19 will create another pride for Taiwan.\n'

Taiwan's Antrodia cinnamomea Gains World Recognition

Retrieved on: 
Thursday, May 13, 2021

Greenyn Biotechnology received USFDA NDI acknowledgement without objection for Antrodia cinnamomea mycelia "Antromax"

Key Points: 
  • It was a great feat for Greenyn, and will certainly boost the morale of the Antrodia industry to devote more resources in the US market.\nA.
  • cinnamomea is an edible fungus that grows on the endangered Cinnamomum kanehirae tree, which is found only in Taiwan.
  • Over the past years, it was difficult to obtain such notification because A. cinnamomea is unknown to the western world; its\' safety data, eating and application history is very limited.
  • It is foreseeable that the health benefit of A. cinnamomea to the world during COVID-19 will create another pride for Taiwan.\n'